BR112015008308A2 - moduladores de quinolinila ligados por metileno do ror-gama-t - Google Patents

moduladores de quinolinila ligados por metileno do ror-gama-t

Info

Publication number
BR112015008308A2
BR112015008308A2 BR112015008308A BR112015008308A BR112015008308A2 BR 112015008308 A2 BR112015008308 A2 BR 112015008308A2 BR 112015008308 A BR112015008308 A BR 112015008308A BR 112015008308 A BR112015008308 A BR 112015008308A BR 112015008308 A2 BR112015008308 A2 BR 112015008308A2
Authority
BR
Brazil
Prior art keywords
ror
syndrome
disorder
disease
gamma
Prior art date
Application number
BR112015008308A
Other languages
English (en)
Inventor
Wang Aihua
Fourie Anne
R Woods Craig
A Kummer David
Venkatesan Hariharan
P Edwards James
Pierce Joan
Barbay Kent
D Kreutter Kevin
A Leonard Kristi
Urbanski Maud
Nishimura Rachel
L Wolin Ronald
Goldberg Steven
Maharoof Umar
Xue Xiaohua
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112015008308A2 publication Critical patent/BR112015008308A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

abstract the present invention comprises compounds of formula i. formula i wherein: r1, r2, r3, r4, r5, r6, r7, r8, and r9 are defined in the specification. the invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. the invention also comprises a method of modulating ror?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1. tradução do resumo resumo patente de invenção "moduladores de quinolinila ligados por metileno do ror-gama-t" a presente invenção refere-se a compostos de fórmula (i). fórmula i em que: r1, r2, r3, r4, r5, r6, r7, r8 e r9 são definidos no relatório descritivo. a invenção compreende também um método para tratamento ou alívio de uma síndrome, distúrbio ou doença, sendo que a dita síndrome, distúrbio ou doença é artrite reumatoide ou psoríase. a invenção compreende, também, um método de modulação da atividade de ror?t em um mamífero através da administração de uma quantidade terapeuticamente eficaz de ao menos um composto conforme definido na reivindicação 1.
BR112015008308A 2012-10-16 2013-10-15 moduladores de quinolinila ligados por metileno do ror-gama-t BR112015008308A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261714419P 2012-10-16 2012-10-16
US201261725528P 2012-11-13 2012-11-13
US201361782257P 2013-03-14 2013-03-14
PCT/US2013/065013 WO2014062658A1 (en) 2012-10-16 2013-10-15 Methylene linked quinolinyl modulators of ror-gamma-t

Publications (1)

Publication Number Publication Date
BR112015008308A2 true BR112015008308A2 (pt) 2017-12-05

Family

ID=49546611

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008308A BR112015008308A2 (pt) 2012-10-16 2013-10-15 moduladores de quinolinila ligados por metileno do ror-gama-t

Country Status (38)

Country Link
US (1) US9290476B2 (pt)
EP (1) EP2909192B1 (pt)
JP (1) JP6466335B2 (pt)
KR (1) KR20150070347A (pt)
CN (1) CN105209453B (pt)
AR (1) AR093017A1 (pt)
AU (1) AU2013331496B2 (pt)
BR (1) BR112015008308A2 (pt)
CA (1) CA2888210C (pt)
CL (1) CL2015000945A1 (pt)
CR (1) CR20150193A (pt)
CY (1) CY1119234T1 (pt)
DK (1) DK2909192T3 (pt)
EA (1) EA026415B1 (pt)
EC (1) ECSP15015022A (pt)
ES (1) ES2632269T3 (pt)
GT (1) GT201500093A (pt)
HK (1) HK1213248A1 (pt)
HR (1) HRP20171082T1 (pt)
HU (1) HUE035335T2 (pt)
IL (1) IL237866B (pt)
LT (1) LT2909192T (pt)
ME (1) ME02794B (pt)
MX (1) MX358508B (pt)
MY (1) MY189505A (pt)
NI (1) NI201500053A (pt)
NZ (1) NZ706775A (pt)
PE (1) PE20150778A1 (pt)
PH (1) PH12015500817B1 (pt)
PL (1) PL2909192T3 (pt)
PT (1) PT2909192T (pt)
RS (1) RS56283B1 (pt)
SG (1) SG11201502369XA (pt)
SI (1) SI2909192T1 (pt)
TW (1) TWI606045B (pt)
UY (1) UY35084A (pt)
WO (1) WO2014062658A1 (pt)
ZA (1) ZA201503418B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860099A1 (en) * 2012-02-13 2013-08-22 Johannes Aebi Imidazolylketone derivatives asd aldosterone synthase inhibitors
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
AP2015008601A0 (en) 2013-03-14 2015-07-31 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
CN105705501B (zh) 2013-09-09 2019-04-19 百时美施贵宝公司 RORγ调节剂
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) * 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
CN105636952A (zh) * 2013-10-15 2016-06-01 詹森药业有限公司 Rorγt的仲醇喹啉基调节剂
US9284308B2 (en) * 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2927153A1 (en) * 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
PE20170137A1 (es) * 2014-05-28 2017-03-05 Glaxosmithkline Ip Dev Ltd Nuevos compuestos
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN114555596A (zh) 2019-09-30 2022-05-27 詹森药业有限公司 放射性标记的mgl pet配体
EP4053109A4 (en) * 2019-10-31 2022-12-21 Jiangsu Hengrui Medicine Co., Ltd. ACID ADDITION SALT BY RORy REGLER
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
WO2021219849A1 (en) 2020-04-30 2021-11-04 Idorsia Pharmaceuticals Ltd Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators
CN112939974B (zh) * 2021-03-11 2023-10-20 中山大学 一种氮杂苯并薁衍生物的制备方法
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
CN118215662A (zh) 2021-10-26 2024-06-18 爱杜西亚药品有限公司 Ccr6受体调节剂
IL312369A (en) 2021-10-28 2024-06-01 Idorsia Pharmaceuticals Ltd CCR6 receptor modulators

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS4826772U (pt) 1971-08-02 1973-03-31
ATE27451T1 (de) 1981-03-24 1987-06-15 Ciba Geigy Ag Acyl-chinolinonderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische praeparate und ihre verwendung.
US4656283A (en) 1982-05-25 1987-04-07 American Cyanamid Company Alkyl esters of substituted 2-methyl-3-quinolinecarboxylic acid and quinoline-2,3-dicarboxylic acid
US4910327A (en) 1982-05-25 1990-03-20 American Cyanamid Company Alkyl esters of substituted 2-methyl-3-quinolinecarboxylic acid and quinoline-2,3-dicarboxylic acid: dialkyl 3-(substituted)phenylaminobut-2-ene-dioates and methods for the preparation thereof
US4710507A (en) 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
FR2634483B2 (fr) 1987-12-29 1994-03-04 Esteve Labor Dr Derives des acides 7-(1-azetidinyl)-1,4-dihydro-4-oxoquinoleine-3-carboxyliques, leur preparation et leur application en tant que medicaments
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
EP0709377B1 (en) 1994-10-27 1999-09-29 Asahi Glass Company Ltd. Process for producing quinolin-2-yl benzoic acid compounds
GB9523267D0 (en) 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
WO1997044339A1 (en) 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE69807222T2 (de) * 1997-06-02 2003-04-17 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
HUP0101999A3 (en) 1997-12-22 2003-06-30 Upjohn Co 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
FR2776388B1 (fr) 1998-03-20 2006-04-28 Lipha Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
BR9911869A (pt) * 1998-07-06 2001-03-27 Janssen Pharmaceutica Nv Inibidores da transferase da proteìna farnesil para o tratamento das artropatias
CN1152716C (zh) 1998-07-06 2004-06-09 詹森药业有限公司 具体内射线感受性的法呢基蛋白质转移酶抑制剂
JP2000169451A (ja) 1998-09-30 2000-06-20 Kyorin Pharmaceut Co Ltd ６，７―ジ置換キノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
TW531533B (en) 1998-12-23 2003-05-11 Janssen Pharmaceutica Nv 1,2-annelated quinoline derivatives having farnesyl transferase and geranylgeranyl transferase inhibiting activity
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
CN1340051A (zh) 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
DE60118889T2 (de) 2000-02-04 2006-11-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
US6838467B2 (en) 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
CA2397475A1 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
JP2003525239A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
EP1267929A2 (en) 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
CA2397256A1 (en) 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064197A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
AU2001246477A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001256166A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397694A1 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations
CA2397240A1 (en) 2000-02-29 2001-09-07 Peter Albert Palmer Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064217A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397448A1 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US6844357B2 (en) 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
WO2002004462A1 (en) 2000-07-12 2002-01-17 Pharmacia & Upjohn Company Oxazinoquinolones useful for the treatment of viral infections
US6624159B2 (en) 2000-07-12 2003-09-23 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1322635B1 (en) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
EP1322644A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
BR0114253A (pt) 2000-10-02 2003-07-01 Janssen Pharmaceutica Nv Antagonistas de receptor de glutamato metabotrópico
DK1339407T3 (da) 2000-11-28 2006-08-14 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
DE60230017D1 (de) 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
EP1363887A1 (en) 2001-03-01 2003-11-26 PHARMACIA & UPJOHN COMPANY Substituted quinolinecarboxamides as antiviral agents
JP2004526776A (ja) 2001-04-25 2004-09-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 悪液質を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6706699B2 (en) 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
AU2002350244A1 (en) 2001-12-20 2003-07-09 Pharmacia And Upjohn Company Pyridoquinoxaline antivirals
US6686356B2 (en) 2001-12-20 2004-02-03 Pharmacia & Upjohn Company Pyridoquinoxaline antivirals
EA009334B1 (ru) 2002-03-29 2007-12-28 Янссен Фармацевтика Н.В. Меченные радиоактивными изотопами производные хинолина и их применение в качестве лигандов метаботропного глутаматного рецептора
EP1541558B1 (en) 2002-08-13 2008-08-13 Shionogi & Co., Ltd. Heterocyclic compounds having hiv integrase inhibitory activity
AU2003262947A1 (en) 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
GB0222516D0 (en) 2002-09-27 2002-11-06 Karobio Ab Novel compounds
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
CA2546300C (en) 2003-11-20 2012-10-02 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4806353B2 (ja) 2003-12-05 2011-11-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン
EA010592B1 (ru) 2003-12-10 2008-10-30 Янссен Фармацевтика Н.В. 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы
BRPI0417543A (pt) 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
EA011277B1 (ru) 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Производные хинолина и их применение в качестве ингибиторов микобактерий
WO2005075428A1 (en) 2004-01-29 2005-08-18 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
JP2005225250A (ja) 2004-02-10 2005-08-25 Murakami Corp 車載用監視装置
MXPA06014543A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolinona como inhibidores de la poli(adp-ribosa)polimerasa-i.
ES2407813T3 (es) 2004-08-04 2013-06-14 Meiji Seika Pharma Co., Ltd. Derivados de quinolina e insecticida que contienen los mismos como constituyente activo
KR100686531B1 (ko) 2004-08-31 2007-02-23 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 아릴아미노메틸프로페닐 벤즈하이드록시아마이드 유도체 및 그의 제조방법
DK1815247T3 (da) 2004-11-05 2013-03-11 Janssen Pharmaceutica Nv Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitet
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JP5112083B2 (ja) 2006-02-03 2013-01-09 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規キノリン誘導体およびこれを有効成分として含有する農園芸用殺菌剤
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
PL2081937T3 (pl) 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
JO3271B1 (ar) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
KR101156845B1 (ko) 2007-05-21 2012-06-18 에스지엑스 파마슈티컬스, 인코포레이티드 헤테로시클릭 키나제 조절제
CN101143845B (zh) 2007-10-15 2010-08-25 中国药科大学 取代喹啉甲酰胍衍生物、其制备方法及其医药用途
AU2009205539B2 (en) 2008-01-18 2013-12-05 Allergan.Inc Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
JP2011511056A (ja) 2008-02-05 2011-04-07 ファイザー・インク Ｃｎｓ障害および代謝障害治療のためのピリジニルアミド
BRPI0912604A2 (pt) 2008-05-13 2019-09-10 Allergan Inc quinolinilmetilimidazóis como agentes terapêuticos
WO2010068296A1 (en) 2008-12-11 2010-06-17 Stiefel Laboratories, Inc. Piperazine carboxamidines as antimicrobial agents
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
CN101899011B (zh) 2009-05-26 2013-01-16 北京大学 氨基二硫代甲酸酯类化合物、其制备方法和应用
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
MX2011013510A (es) 2009-06-25 2012-03-07 Amgen Inc Compuestos heterociclicos y sus usos.
IN2012DN01453A (pt) 2009-08-20 2015-06-05 Novartis Ag
EP2368886A1 (en) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
WO2011112264A1 (en) 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
CN105962259A (zh) 2010-04-15 2016-09-28 卓莫赛尔公司 用于减小或消除苦味的化合物、组合物和方法
EP2638014B1 (en) * 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
EP2678052B1 (en) 2011-02-24 2018-09-26 Emory University Jab1 blocking compositions for ossification and methods related thereto
BR112013027670B1 (pt) 2011-04-28 2021-11-09 Japan Tobacco Inc Composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
EP2800745B1 (en) 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
AU2013331496B2 (en) 2017-07-27
LT2909192T (lt) 2017-07-10
ES2632269T3 (es) 2017-09-12
CN105209453B (zh) 2017-06-20
WO2014062658A1 (en) 2014-04-24
HUE035335T2 (en) 2018-05-02
ZA201503418B (en) 2017-11-29
JP2015536320A (ja) 2015-12-21
CY1119234T1 (el) 2018-02-14
NZ706775A (en) 2018-10-26
PH12015500817A1 (en) 2015-06-08
SI2909192T1 (sl) 2017-08-31
PH12015500817B1 (en) 2015-06-08
US20140107094A1 (en) 2014-04-17
PT2909192T (pt) 2017-08-04
JP6466335B2 (ja) 2019-02-06
CA2888210A1 (en) 2014-04-24
TWI606045B (zh) 2017-11-21
EP2909192A1 (en) 2015-08-26
HK1213248A1 (zh) 2016-06-30
EA201590736A1 (ru) 2015-09-30
RS56283B1 (sr) 2017-12-29
MX2015004783A (es) 2015-08-14
MX358508B (es) 2018-08-22
CN105209453A (zh) 2015-12-30
ME02794B (me) 2018-01-20
CL2015000945A1 (es) 2015-08-28
EP2909192B1 (en) 2017-05-17
CR20150193A (es) 2015-05-18
PL2909192T3 (pl) 2017-09-29
WO2014062658A8 (en) 2014-07-10
SG11201502369XA (en) 2015-05-28
GT201500093A (es) 2017-09-26
AU2013331496A1 (en) 2015-04-09
ECSP15015022A (es) 2016-01-29
TW201427969A (zh) 2014-07-16
US9290476B2 (en) 2016-03-22
KR20150070347A (ko) 2015-06-24
UY35084A (es) 2014-04-30
PE20150778A1 (es) 2015-05-23
NI201500053A (es) 2020-03-18
CA2888210C (en) 2021-02-09
DK2909192T3 (en) 2017-08-07
EA026415B1 (ru) 2017-04-28
AR093017A1 (es) 2015-05-13
HRP20171082T1 (hr) 2017-10-06
IL237866B (en) 2018-05-31
MY189505A (en) 2022-02-16

Similar Documents

Publication Publication Date Title
BR112015008308A2 (pt) moduladores de quinolinila ligados por metileno do ror-gama-t
BR112015008515A2 (pt) moduladores de ror t de quinolinila ligada à heteroarila
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
PH12015500776A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
BR112012031873A2 (pt) antagonistas de ciclo-hexil-azetidinila do ccr2
MX2014013499A (es) Moduladores alostericos de receptor alfa 7 nicotinico de acetilcolina, sus derivados y usos de los mismos.
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112014027359A2 (pt) moduladores da série de reação complementar e usos dos mesmos
BR112015022096A2 (pt) moduladores de canal de sódio para o tratamento da dor
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
CU24177B1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
BR112017008842A2 (pt) tiazóis como moduladores de ror?t
BR112016008158A2 (pt) Moduladores de ror-gama-t de quinolinila ligados a metileno
BR112014003704A2 (pt) moduladores ror gama
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
NZ700733A (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
BR112017008816A2 (pt) álcoois trifluormetílicos como moduladores do roryt
BR112016008215A2 (pt) moduladores de quinolinila ligados por alquila de roryt
BR112018071942A2 (pt) tiazóis de 6-aminopiridin-3-ila como moduladores de rorgamat
BR112015004523A2 (pt) compostos de tetraciclina
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112016000338A8 (pt) composto enriquecido em deutério de fórmula estrutural i, composição farmacêutica, e usos de um composto
BR112016008201A2 (pt) Moduladores de quinolinila ligados à heteroarila de roryt
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements